In an editorial, one expert said the choice of DOAC in VTE is “no longer a toss-up,” with apixaban the clear winner.

Favorable safety shown in secondary prevention for acute venous thromboembolism ...

The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear winner: while both drugs work well to prevent recurrent blood clots, apixaban ...

Please provide your email address to receive an email when new articles are posted on . Overall, 1,144 bleeding events occurred by the 1-year follow-up period. There were 577 ischemic stroke or ...

Rivaroxaban, a direct oral anticoagulant (DOAC), demonstrated greater efficacy and similar safety compared with warfarin in patients with chronic kidney disease and atrial fibrillation. Rivaroxaban, a ...

Please provide your email address to receive an email when new articles are posted on . A systematic review and meta-analysis of nine trials comparing non-vitamin K oral anticoagulants with low-dose ...

Patients with atrial fibrillation who use diltiazem combined with apixaban or rivaroxaban face an increased risk for serious bleeding events compared with those who use metoprolol.

The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear winner: while both drugs work well to prevent recurrent blood clots, apixaban ...

We conducted an international, open-label, randomized, blinded-outcome-assessment trial involving 1284 patients who had undergone successful catheter ablation for atrial fibrillation at least 1 year ...